Christiana Stamoulis - 25 Feb 2026 Form 4 Insider Report for Keenova Therapeutics plc

Role: President and CFO
Signature: /s/ Mark Tyndall, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 25 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 26 Feb 2026, 21:02:47 UTC
Previous filing: 23 Dec 2025
Next filing: 02 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Stamoulis Christiana	President and CFO	440 ROUTE 22 EAST, SUITE 302, BRIDGEWATER	/s/ Mark Tyndall, Attorney-in-Fact	26 Feb 2026	0001502917

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction		Restricted Stock Units	Award	$0	+101,262	+139%	$0.000000	174,181	25 Feb 2026	Ordinary Shares	101,262		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.
F2	The RSUs will vest ratably on each of the first three anniversaries of February 25, 2027.

Remarks:

This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.